Laboratory of Membrane Transport for Biopharmaceutics, Faculty of Pharmacy, Takasaki University of Health and Welfare, Takasaki, Japan.
Laboratory of Membrane Transport for Biopharmaceutics, Faculty of Pharmacy, Takasaki University of Health and Welfare, Takasaki, Japan.
Prostaglandins Other Lipid Mediat. 2023 Apr;165:106714. doi: 10.1016/j.prostaglandins.2023.106714. Epub 2023 Jan 24.
SLCO2A1 functions as a prostaglandin (PG) influx transporter to facilitate intracellular oxidation of PGs and its defect causes dysregulation of PG signaling and metabolism. This study aimed to clarify effects of N-glycosylation on functional SLCO2A1 expression. Putative N-glycosylation site(s) (N134, N478, and/or N491) of human SLCO2A1 were mutated to Q and wild-type (WT) and mutant forms were expressed in HEK293 and human epithelial cells. Molecular weight of WT decreased to nearly 55 kDa by PNGase F treatment and was identical to that of triple mutant (TM, i.e., N134Q/N478Q/N491Q). Transport affinity of TM for PGE (K of 392.7 nM) was comparable to that of WT (K of 328.5 nM); however, immunoassays showed that TM cell surface expression remained at 24% of WT in HEK293 cells, resulting in a reduced cellular PGE uptake. These results suggest N-glycosylation modifies cellular PGE uptake by decreasing SLCO2A1 localization to the plasma membrane.
SLCO2A1 作为一种前列腺素 (PG) 内流转运体,促进 PGs 的细胞内氧化,其功能缺陷导致 PG 信号和代谢失调。本研究旨在阐明 N-糖基化对功能性 SLCO2A1 表达的影响。人 SLCO2A1 的假定 N-糖基化位点 (N134、N478 和/或 N491) 突变为 Q,野生型 (WT) 和突变型分别在 HEK293 和人上皮细胞中表达。PNGase F 处理使 WT 的分子量降低至近 55 kDa,与三突变体 (TM,即 N134Q/N478Q/N491Q) 相同。TM 对 PGE 的转运亲和力 (K 值为 392.7 nM) 与 WT (K 值为 328.5 nM) 相当;然而,免疫测定显示 TM 在 HEK293 细胞中的细胞表面表达仍为 WT 的 24%,导致细胞内 PGE 摄取减少。这些结果表明,N-糖基化通过降低 SLCO2A1 向质膜的定位来调节细胞内 PGE 的摄取。